Deploying world-leading capabilities through strategic partnerships

IMIDomics is supported by an extensive network of industry-leading partners at each stage of our Clinical Discovery Engine



Vall d’Hebron Institute of Research

VHIR is a public sector institution that promotes and develops biomedical research, innovation, and teaching at Vall d'Hebron University Hospital. Since 1994, VHIR has been working to identify and implement new solutions to society's health problems, achieving leadership and excellence in clinical and translational biomedical research in the national and international spheres.


DoCTIS is an EU-funded multicentric project aimed at addressing the urgent need to discover effective therapeutic strategies for IMIDs.

IMIDomics joins this broad academic partnership to explore combination therapies.

University of Barcelona

UB is an entity, founded in 1450, committed to excellence in education and research across various fields. It contributes to innovation and business competitiveness and, in general, to the progress of science and artistic creation by means of the creation, transmission and dissemination to the society of the scientific, technical and professional knowledge that generates.

Discovery and Development



Evotec has established itself as a global platform company, leveraging its data-driven multimodality platform for both proprietary as well as partnered research, and applying a unique combination of innovative technologies for the discovery and development of first-in-class and best-in-class pharmaceutical products. Evotec operates globally with more than 4,500 highly qualified people at 17 sites in six countries across Europe and the USA.



Bristol Myers Squibb

Bristol Myers Squibb combines the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation.


Help us shape the future of immune-mediated inflammatory disease (IMID) medicines


Our work is made possible through our partnerships with industry-leading experts and organizations. We’re always looking for opportunities to expand our network and accelerate the development of medicines for IMID patients. If you are interested in working with us, we’d love to hear from you.

Discovering and developing the next generation of medicines for immune-mediated inflammatory diseases